Understand the source comparison
Wolverine Stack Pre-Research Checklist: Comprehensive Comparison
Receptor Pathway Mapping Identify GH secretagogue type (GHRP vs GHRH), tissue repair mechanism (VEGF vs NO pathway), metabolic targets (AMPK vs insulin pathway) 30–40% reduced efficacy from receptor competition; wasted second peptide acting through same pathwa
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Receptor Pathway Mapping
- Identify GH secretagogue type (GHRP vs GHRH), tissue repair mechanism (VEGF vs NO pathway), metabolic targets (AMPK vs insulin pathway)
- 30–40% reduced efficacy from receptor competition; wasted second peptide acting through same pathway
- Pre-purchase. 2–4 hours research
- Requires second protocol restart with different compound selection
- CRITICAL. Most common stack failure mode. Cannot be corrected mid-protocol without resetting receptor sensitivity.
- Half-Life Compatibility
- Match peptide clearance rates to dosing schedule; identify long-acting (MK-677: 24hr) vs short-acting (GHRP-2: 90min) compounds
- Masking of short-acting compound effects by sustained long-acting receptor occupancy; functional redundancy
- Pre-purchase. 1 hour research
- Cannot correct without protocol redesign
- HIGH. Determines optimal injection timing windows. Long+short combos require 2–3hr spacing minimum.
- Reconstitution Solvent Match
- Verify bacteriostatic water vs sterile water vs acetic acid requirements per compound; check acetate salt pH sensitivity
- 15–20% degradation over 14 days for pH-incompatible combinations; complete potency loss if frozen
- Pre-reconstitution. 30min per compound
- Requires new peptide vials if original batch mixed incorrectly
- CRITICAL. Irreversible if wrong solvent used. Acetate-salt peptides fail in bacteriostatic water.
- Storage Protocol Verification
- Confirm refrigeration 2–8°C capacity; acquire light-protective amber vials or storage; validate zero freeze-thaw exposure
- 40–60% bioactivity loss from single freeze-thaw cycle; 25–30% loss from 72hr light exposure
- Pre-reconstitution. Equipment acquisition before first dose
- New peptide vials required if storage compromised
- HIGH. Temperature/light excursions undetectable visually but destroy peptide structure permanently.
- Baseline Biomarker Panel
- IGF-1, ALT, AST, creatinine, eGFR, fasting glucose, lipid panel; optional: DEXA scan for body composition
- No objective measurement of protocol efficacy; inability to distinguish peptide effects from natural variation
- Week 0 before first injection
- Retrospective baseline impossible; requires waiting 8–12 weeks for washout before re-baselining
- MEDIUM-HIGH. Biomarkers cost $150–300 but provide only method to verify peptides are working as intended.
- Interaction Screening
- Check current medications for GH axis interference (corticosteroids, thyroid meds); verify no active infections or acute injuries
- Blunted GH response from glucocorticoid suppression; contraindication for tissue repair peptides during acute infection
- Pre-purchase. Medication review with ordering physician
- May require temporary protocol delay or medication adjustment
- MEDIUM. Some interactions absolute contraindications (active malignancy + GH secretagogues); others dose-dependent.